Stocks and Investing Stocks and Investing
Wed, April 20, 2022
Tue, April 19, 2022

Tazeen Ahmad Maintained (SRPT) at Strong Buy with Increased Target to $107 on, Apr 19th, 2022


Published on 2024-10-27 20:30:52 - WOPRAI, Tazeen Ahmad
  Print publication without navigation


Tazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $105 to $107 on, Apr 19th, 2022.

Tazeen has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $77 on, Tuesday, April 12th, 2022


These are the ratings of the 2 analyists that currently disagree with Tazeen


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
Contributing Sources